TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26057085
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide bleaching agent
Study: 16390282
Drug: Constructive worry
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constructive worry intervention (recording possible solutions to worries)
Study: 1793675
Drug: oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral oestradiol valerate in a cyclical combination with cyproterone acetate (n = 19)
Study: 6422478
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg fenoprofen calcium 3-times daily
Study: 6422478
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg naproxen sodium 3-times daily
Study: 24621960
Drug: L-citrulline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-citrulline (10 g)
Study: 24621960
Drug: Placebo (L-alanine)
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (L-alanine)
Study: 15763437
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (8 g/day for 6 weeks)
Study: 10483898
Drug: Ala‐Gln (Dipeptiven,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ala‐Gln (Dipeptiven, 0.50 g/kg per day)
Study: 8743406
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of naproxen
Study: 8743406
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of naproxen
Study: 1686440
Drug: Previous formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous formula (Mg++ salt of N-acetyl-aspartylglutamic acid)
Study: 6435085
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (Theo-Dur)
Study: 30136743
Drug: Gesture-Verbal Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gesture-Verbal Treatment (GVT)
Study: 30413519
Drug: Smartphone-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based problem-solving therapy (PST) and behavioural activation (BA) apps (Kaiketsu-App and Genki-App) plus treatment as usual (TAU)
Study: 30413519
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control with treatment as usual (TAU) alone
Study: 26856215
Drug: Normal-low potassium
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-low potassium target (nLP group, 4.0 mmol/L)
Study: 26856215
Drug: Normal-high potassium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-high potassium target (nHP group, 4.5 mmol/L)
Study: 25417401
Drug: Xinfeng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng capsule (XFC) treatment group
Study: 21958494
Drug: Meropenem (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (20 mg/kg q12h or q8h depending on age)
Study: 18431478
Drug: Oral amoxycillin
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amoxycillin (31-54 mg/Kg/day, in three divided doses for three days)
Study: 16191242
Drug: Memantine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine at a standard daily dose of 10 mg b.i.d.
Study: 10798610
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (n-3 PUFAs) - fish oil extract (EPA 3.2 g, DHA 2.4 g)
Study: 8689472
Drug: Psychoanalytical group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytical group therapy
Study: 1686811
Drug: D,L-fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-fenfluramine (60 mg, oral)
Study: 31668850
Drug: Palbociclib plus
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib plus endocrine therapy (oral exemestane 25 mg per day for 28 days, oral palbociclib 125 mg per day for 21 days every 4 weeks, plus leuprolide 3·75 mg subcutaneously every 4 weeks)
Study: 31668850
Drug: Capecitabine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (oral capecitabine 1250 mg/m2 twice daily for 2 weeks every 3 weeks)
Study: 17616331
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment (n=24)
Study: 17616331
Drug: HIV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV treatment only (n=115)
Study: 15832066
Drug: Self-exposure cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-exposure cognitive behaviour therapy (CBT) via FearFighter (FF)
Study: 9817161
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of antibodies to IL-3, IL-5 and GM-CSF
Study: 2693162
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 and 600 mg daily
Study: 29725853
Drug: Duo (D)
Normalized name: Effaclar Duo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duo (D) implant
Study: 29725853
Drug: Integra (IN)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integra (IN) implant
Study: 29725853
Drug: Standard geometry,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard geometry, Duo (D), Compact (C), Infra (IF) implants
Study: 21802124
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg daily for ≤30 days)
Study: 21802124
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg retard daily for ≤30 days)
Study: 19406908
Drug: Clodronate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 0.5 mg one IA injection/week for 4 weeks
Study: 19406908
Drug: Clodronate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1 mg one IA injection/week for 4 weeks
Study: 19406908
Drug: Clodronate 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 2 mg one IA injection/week for 4 weeks
Study: 19406908
Drug: Clodronate 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1 mg two IA injections/week for 2 weeks
Study: 19406908
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) 20 mg one IA injection/week for 4 weeks
Study: 1357998
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (combined regimens)
Study: 30110008
Drug: Cold tumescence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold tumescence anesthesia solution (4 ℃)
Study: 30110008
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature tumescence anesthesia solution (24 ℃)
Study: 25079064
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (verteporfin PDT and ranibizumab)
Study: 9267791
Drug: Total Androgen
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Androgen Blockade (TAB) by bilateral orchiectomy and flutamide 250 mg t.i.d.
Study: 9267791
Drug: Combined Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Total Androgen Blockade plus weekly epirubicin 25 mg/m2 i.v. for 18 weeks (E-TAB)
Study: 9267791
Drug: Combined Total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Total Androgen Blockade plus weekly epirubicin (E-TAB)
Study: 7506154
Drug: Nimesulide 100mg
Normalized name: nimesulide 100 MG
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100mg 3 times daily
Study: 3101530
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (8 patients, 5% dextrose in water solution)
Study: 31589276
Drug: Free distribution
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free distribution of essential medicines (n = 395)
Study: 24840109
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days starting on day 5 of menses (Group 1)
Study: 24840109
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg daily for 5 days starting the next day after finishing medroxyprogesterone acetate (MPA) (Group 2)
Study: 24840109
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (Group 2)
Study: 22872647
Drug: Entecavir 1.0
Normalized name: ENTECAVIR 1.0 mg ORAL TABLET, FILM COATED [BARACLUDE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1.0 mg/day
Study: 12825872
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FS and FOBT
Study: 10713235
Drug: Modified Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Ringer's solution
Study: 1353507
Drug: nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5 mg once a day (n = 26)
Study: 1353507
Drug: nifedipine sustained-release
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine sustained-release 20 mg bid (n = 25)
Study: 30894212
Drug: Epacadostat (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat (25, 50, 100, or 300 mg BID; 75 mg daily; or 50 mg BID intermittent) plus ipilimumab 3 mg/kg every 3 weeks
Study: 30894212
Drug: Epacadostat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat (various doses) plus ipilimumab
Study: 30894212
Drug: Epacadostat (≥25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat (≥25 mg BID) plus ipilimumab
Study: 23114185
Drug: Loxostylis alata
Normalized name: Dioscorea alata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxostylis alata extract at doses of 100 mg/kg and 200 mg/kg
Study: 23114185
Drug: Ketoconazole at
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole at a dose of 60 mg/kg
Study: 17065169
Drug: i.v. saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. saline 5 ml (control)
Study: 11868855
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (dietary control, exercise) and placebo capsules
Study: 9014542
Drug: Doxapram (0.18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (0.18 mg.kg‐1)
Study: 9014542
Drug: Pethidine (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (0.35 mg.kg‐1)
Study: 8198023
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg every PM for 6 weeks followed by 20 mg twice daily for an additional 6 weeks
Study: 3480840
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal suppository (2.5 mg PGE2 in Witepsol S55)
Study: 3480840
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal suppository
Study: 27194403
Drug: Intravenous Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Plasma-Lyte 148 at 2 mL·kg(‐1) (low volume)
Study: 27194403
Drug: Intravenous Plasma-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Plasma-Lyte 148 at 20 mL·kg(‐1) (high volume)
Study: 16896786
Drug: Sustained-release chrono
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release chrono VPA (ChVbid, ChVom, ChVoe)
Study: 12831522
Drug: Tinidazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (50 mg/kg, as a single dose)
Study: 12831522
Drug: Chloroquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (10 mg/kg twice daily for 5 days)
Study: 2127744
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g administered orally 1 hour before exercise)
Study: 2127744
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered orally 1 hour before exercise)
Study: 36754
Drug: Phenothiazines for
Normalized name: 10-(2-diethylaminopropyl)phenothiazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenothiazines for narcotic analgesic‐induced emesis
Study: 21215445
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg vitamin D(3) administered at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment.
Study: 21215445
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment.
Study: 21215445
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg vitamin D(3) in patients with tt genotype of TaqI vitamin D receptor polymorphism.
Study: 21215445
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in patients with tt genotype of TaqI vitamin D receptor polymorphism.
Study: 21215445
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg vitamin D(3) at 56 days.
Study: 18798851
Drug: Basiliximab plus
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab plus steroids, mycophenolate mofetil and early initiation of cyclosporin A (CsA) at 3 mg/kg/d within 24 h post-RT
Study: 18798851
Drug: Basiliximab plus
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab plus steroids, mycophenolate mofetil and early initiation of cyclosporin A (CsA) at 5 mg/kg/d within 24 h post-RT
Study: 18798851
Drug: Basiliximab plus
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Basiliximab plus steroids, mycophenolate mofetil and delayed initiation of cyclosporin A (CsA) at 5 mg/kg/d after 7-10 d
Study: 17146635
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) using polymyxin E, tobramycin, and amphotericin B in throat and gut throughout ICU treatment combined with cefotaxime for 4 days
Study: 14975783
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VRET) using a head-mounted display (HMD) (low presence)
Study: 14975783
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VRET) using a computer automatic virtual environment (CAVE) (high presence)
Study: 11303585
Drug: Soymilk (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk (400 ml daily for 8 weeks)
Study: 9207869
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemoradiotherapy with an anthracenedione (50 Gy in 25 fractions over 5 weeks, boost of 15 Gy to the tumor bed when indicated) and chemotherapy (5-fluorouracil, mitoxantrone, and cyclophosphamide at 21-day intervals for 4 to 6 cycles)
Study: 8205090
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline (PTX) 400 mg every 4 hours from day -10 until day +35 or discharge
Study: 3109069
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 25 mg/day
Study: 3109069
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 125 mg/day
Study: 3109069
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 250 mg/day
Study: 3109069
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 500 mg/day
Study: 22440975
Drug: 0.45 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/kg dexamphetamine
Study: 23545372
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help treatment of pediatric obesity (GSH-PO)
Study: 21576556
Drug: Intranasal aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal aqueous triamcinolone acetonide, administered once daily for 6 weeks
Study: 21576556
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered once daily for 6 weeks
Study: 21576556
Drug: Intranasal aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal aqueous triamcinolone acetonide
Study: 15095852
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/day for 8 weeks, 6 mg/day for 4 weeks)
Study: 15095852
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg/day for 4 weeks, tapering for 8 weeks)
Study: 23916925
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg twice daily (n = 30)
Study: 18069016
Drug: Subacromial steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial steroid injections
Study: 18069016
Drug: Both physiotherapy
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both physiotherapy and steroid injections
Study: 16794461
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (150 mg of cocoa flavanols for 5 days)
Study: 16794461
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (450 mg of flavanols - single acute dose)
Study: 30590423
Drug: Increased insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased insulin resistance (measured by HOMA-IR)
Study: 26849119
Drug: Carbocysteine 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocysteine 1500 mg daily
Study: 25132282
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (30 mg of lansoprazole, 1g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily for 10 days)
Study: 25132282
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (30 mg of lansoprazole, 1g of amoxicillin, and 500 mg of clarithromycin, twice daily for 10 days)
Study: 10933337
Drug: Butorphanol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (3 mg/70 kg)
Study: 10933337
Drug: Butorphanol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (6 mg/70 kg)
Study: 10933337
Drug: Morphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15 mg/70 kg)
Study: 10933337
Drug: Morphine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (30 mg/70 kg)
Study: 10933337
Drug: Lorazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4 mg/70 kg)
Study: 8156482
Drug: 5-FU (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (425 mg/m2) and LV (20 mg/m2) for 5 days
Study: 8156482
Drug: 5-FU (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (425 mg/m2) and LV (20 mg/m2) plus CDDP (20 mg/m2 for 4 consecutive days)
Study: 3073655
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of CF with constant dose of FUra 400 mg/m2
Study: 3073655
Drug: Oral CF
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CF with escalating doses of FUra
Study: 29602626
Drug: Intra-alveolar administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-alveolar administration of epsilon-aminocaproic acid (EACA) and daily gentle rinsing with EACA mouthwash
Study: 28133766
Drug: RBP-7000 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-7000 (90 mg and 120 mg)
Study: 11115050
Drug: IFN-alpha2b (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 24 weeks
Study: 11115050
Drug: IFN-alpha2b (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 48 weeks
Study: 9058441
Drug: Diet providing
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet providing 20 g/d lactose
Study: 8375836
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment program (18 weeks)
Study: 8375836
Drug: Control (delayed-treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (delayed-treatment)
Study: 3890505
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil (16 mg)
Study: 3890505
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (10 mg)
Study: 3890505
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (verapamil and metoprolol)
Study: 3890505
Drug: Metoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10 mg) during upright bicycle exercise
Study: 3890505
Drug: Verapamil (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (16 mg) during upright bicycle exercise
Study: 3890505
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy during upright bicycle exercise
Study: 30797084
Drug: Dalbavancin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin 1500 mg intravenously as a single dose